Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 12/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | DDO | Q99489 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482246 | 1.00 | PARP1 (0.44) | PARP1BRD4ATAD2KDM4ETSHR | |
| SCHEMBL30482206 | 0.88 | PARP1 (0.43) | PARP1BRD4ATAD2KDM4ETSHR | |
| SCHEMBL29266513 | 0.85 | PARP1 (0.44) | PARP1BRD4ATAD2KDM4ETSHR | |
| SCHEMBL25310402 | 0.85 | PARP1 (0.49) | PARP1BRD4ATAD2KDM4ETSHR | |
| SCHEMBL30617995 | 0.85 | PARP1 (0.44) | PARP1BRD4ATAD2KDM4ETSHR | |
| SCHEMBL30482271 | 0.82 | PARP1 (0.48) | PARP1BRD4ATAD2KDM4ETSHR | |
| SCHEMBL30482251 | 0.77 | PARP1 (0.33) | PARP1DAODDO | |
| SCHEMBL25376240 | 0.77 | PARP1 (0.33) | PARP1DAODDO | |
| SCHEMBL25310064 | 0.76 | BRD4 (0.42) | PARP1BRD4ATAD2DAODDO | |
| SCHEMBL30482258 | 0.76 | BRD4 (0.42) | PARP1BRD4ATAD2DAODDO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12384780-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4469449-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4466269-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240368162-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2024-11-07 | — | — | US | disclosed |
| US-11939329-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023146957-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146957-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023141290-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141290-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384780-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | PARP1 1/4885BRD4 37/4885ATAD2 1007/4885 |
| US-11939329-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | PARP1 1/4885BRD4 37/4885ATAD2 1007/4885 |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885BRD4 37/4885ATAD2 1007/4885 |
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP16 | PARP1 1/4885BRD4 28/4885ATAD2 1674/4885 |
| US-20240368162-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885BRD4 37/4885ATAD2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.